Practical Considerations for Use of Insulin/Glucagon-Like Peptide 1 Receptor Agonist Combinations in Older Adults With Type 2 Diabetes.

Over 25% of adults ≥65 years of age have type 2 diabetes (T2D). Individualization of care is important in older adults with T2D, with treatment targets and therapeutic approaches informed by patient-specific medical, psychosocial, functional, and social considerations. Fixed-ratio combination injectable products offer unique benefits in older adults, including reduction of both fasting and postprandial glucose, low hypoglycemia risk, lack of weight gain, fewer gastrointestinal side effects, strong durability of effect, and the potential for medication regimen simplification.